The clinical phase II trial CATCOVID initiated by the Berlin Institute of Health at Charité (BIH) has cleared the final regulatory hurdles with the receipt of a positive ethics committee vote and with approval from the Federal Institute for Drugs and Medical Devices (BfArM), enrolling its first patient this week at University of Leipzig Medical Center. In preliminary studies, BIH scientists had discovered that the immune system reacts with an augmented immune response in cases of severe COVID-19 progression. They also identified an interesting target molecule on immune cells.